This study is in progress, not accepting new patients
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Dates
- study startedestimated completion
- Principal Investigator
- by Hope Rugo
Description
Summary
Official Title
Keywords
Eligibility
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Merck Sharp & Dohme LLC
- Links
- Merck Oncology Clinical Trial Information
- ID
- NCT02819518
- Phase
- Phase 3 Breast Cancer Research Study
- Study Type
- Interventional
- Participants
- At least 882 people participating
- Last Updated